Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities

BACKGROUND: Phase I studies rely on investigators to accurately attribute of adverse events as related or unrelated to study drug. This information is ultimately used to help establish a safe dose. Patterns of physician attribution in the Phase I setting have not been widely studied and assessing th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Eaton, Anne, Iasonos, Alexia, Gounder, Mrinal M, Pamer, Erika G, Drilon, Alexander, Vulih, Diana, Smith, Gary L, Percy Ivy, S., Spriggs, David R, Hyman, David M
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4819316/
https://ncbi.nlm.nih.gov/pubmed/26324741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0339
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados